Paul David
Overview
Explore the profile of Paul David including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
David P, Kouhestani D, Hansen F, Paul S, Czubayko F, Karabiber A, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40003965
The poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is largely due to several challenges, such as late diagnosis, early metastasis, limited response to chemotherapy, aggressive tumor biology, and high rates...
2.
Hansen F, Mittelstadt A, Clausen F, Knoedler S, Knoedler L, Klockner S, et al.
Sci Rep
. 2024 Sep;
14(1):21164.
PMID: 39256468
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, presenting a persisting global health burden. Neutrophils have a double-edged role in tumor progression exhibiting both pro-tumor and anti-tumor...
3.
Hansen F, David P, Weber G
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927922
Gastrointestinal (GI) tumors pose a significant global health burden, necessitating the exploration of novel therapeutic approaches. Plasmacytoid dendritic cells (pDCs) play a crucial role in tumor immunity, exhibiting both anti-tumor...
4.
Mittelstadt A, Anthuber A, David P, Podolska M, Benard A, Brunner M, et al.
Front Immunol
. 2024 Jun;
15:1253072.
PMID: 38846943
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer and peritoneal dissemination is one major cause for this poor prognosis. Exosomes have emerged as promising biomarkers...
5.
Hartwig C, Muller J, Klett H, Kouhestani D, Mittelstadt A, Anthuber A, et al.
Mol Cancer
. 2024 Feb;
23(1):28.
PMID: 38308296
Background: Current diagnostics for the detection of pancreato-biliary cancers (PBCs) need to be optimized. We therefore propose that methylated cell-free DNA (cfDNA) derived from non-invasive liquid biopsies serves as a...
6.
Davwar P, David P, Imoh L, Duguru M, Zawaya K, Tsok Y, et al.
Afr Health Sci
. 2024 Jan;
23(2):81-87.
PMID: 38223595
Background: Aflatoxin B1causes damage to the DNA by the alkylation of bases and P53 mutation. Exposure to this mycotoxin is associated with the development of liver cancer. Measures to reduce...
7.
David P, Mittelstadt A, Kouhestani D, Anthuber A, Kahlert C, Sohn K, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046585
Worldwide, gastrointestinal (GI) cancers account for a significant amount of cancer-related mortality. Tests that allow an early diagnosis could lead to an improvement in patient survival. Liquid biopsies (LBs) due...
8.
Benard A, Hansen F, Uhle F, Klosch B, Czubayko F, Mittelstadt A, et al.
Front Immunol
. 2023 Mar;
14:1140630.
PMID: 36911737
Rationale: Sepsis, a global health burden, is often complicated by viral infections leading to increased long-term morbidity and mortality. Interleukin-3 (IL-3) has been identified as an important mediator amplifying acute...
9.
Hansen F, David P, Akram M, Knoedler S, Mittelstadt A, Merkel S, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672313
Pancreatic ductal adenocarcinoma (PDAC) ranks among the most fatal cancer diseases, widely accepted to have the most dismal prognoses. Although immunotherapy has broadly revolutionized cancer treatment, its value in PDAC...
10.
Cho Y, Kim H, Benard A, Woo H, Czubayko F, David P, et al.
Sci Adv
. 2022 Sep;
8(38):eabq4022.
PMID: 36129990
Electrochemiluminescence (ECL) has an inherently low background and enables precise chemical reactions through electrical control. Here, we report an advanced ECL system, termed ECLipse (ECL in paired signal electrode). We...